COmparison of Clarus and Optos Ultrawide Field Imaging Systems for Geographic Atrophy

Description

The goal of this clinical trial is to compare measurements of geographic atrophy (GA) area between several types of imaging, in order to assess accuracy. The main question to answer is which imaging device provides measurements that are most similar to the standard of care device. Participants will be patients of a retina doctor at University Station Eye Clinic with geographic atrophy, and can expect to be in the study for 60-75 minutes.

Conditions

Macular Degeneration, Age Related, Geographic Atrophy

Talk to us

Study Overview

On this page

Study Details

Study overview

The goal of this clinical trial is to compare measurements of geographic atrophy (GA) area between several types of imaging, in order to assess accuracy. The main question to answer is which imaging device provides measurements that are most similar to the standard of care device. Participants will be patients of a retina doctor at University Station Eye Clinic with geographic atrophy, and can expect to be in the study for 60-75 minutes.

COmparison of Clarus and Optos Ultrawide Field Imaging Systems for Geographic Atrophy (COCO-GA) Protocol

COmparison of Clarus and Optos Ultrawide Field Imaging Systems for Geographic Atrophy

Condition
Macular Degeneration, Age Related
Intervention / Treatment

-

Contacts and Locations

Madison

University of Wisconsin, Madison, Wisconsin, United States, 53705

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * 50 years or older and may be either male or female and may be of any race
  • * Established diagnosis of GA due to AMD
  • * GA characteristics: GA area of between 1.25 mm² and 23 mm², with seventy percent of eyes having GA area ranging from 2.5 mm² to 17.5 mm². GA may be unifocal or multifocal. GA may be subfoveal or extrafoveal, with twenty-five percent of eyes having subfoveal GA. The presence of concurrent peripapillary atrophy will not exclude subjects from participation
  • * Willing to participate as evidenced by signing the written informed consent
  • * Unable to tolerate opthalmic imaging
  • * Presence of neovascular AMD on OCT as confirmed by an ophthalmologist
  • * Presence of significant media opacity preventing adequate retinal imaging
  • * Presence of concurrent retinal disease which may confound assessment

Ages Eligible for Study

50 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

University of Wisconsin, Madison,

Amitha Domalpally, MD, PhD, PRINCIPAL_INVESTIGATOR, University of Wisconsin, Madison

Study Record Dates

2025-03